Future directions should prioritize RCTs targeting early-stage glaucoma, with primary endpoints encompassing both structural (e.g., OCT-based RGC metrics) and functional (e.g., visual field preservation) outcomes, to validate the potential of GLP-1RAs as a true disease-modifying strategy in glaucoma management
and was previously employed at Novo Nordisk
While most GLP-1 shortages resolved in early 2025, regional supply issues can still arise
This is why some clinicians, including Paloma health care providers who prescribe GLP-1 drugs, monitor thyroid function more closely after initiating a GLP-1
A., Liu, Z., Munoz Sandoval, P., Rodriguez, R
Although technically challenging, this should be further investigated, especially in light of the neuroimaging findings in ME/CFS, described in the following paragraphs